NEW FREE! REAL-TIME QUOTES

BullsEye -- Insights For Active Traders

Browse Archives

« November 2009  
Su Mo Tu We Th Fr Sa
1 2 4 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

RagingBull RSS Feeds

Featured Articles Featured Articles

Trader's Lab Trader's Lab

Advanced GET Trading Advanced GET Trading


RTTNews storyPoniard Pharma Nearing D-Day - Stock To Watch

Fri Nov 06 08:56:00 2009 EST

(RTTNews) - Poniard Pharmaceuticals Inc. (PARD) is only days away from announcing the much-awaited late-stage trial results of its experimental drug Picoplatin in small cell lung cancer. The top-line results of the study dubbed SPEAR are expected to be released this month.

If trial results pan out the way they are expected, Poniard will initiate a rolling submission of a New Drug Application with the FDA for Picoplatin as a treatment for refractory or recurrent small cell lung cancer this year. The primary efficacy endpoint of the trial is overall survival. The company will also explore a potential development and commercialization partnership for Picoplatin to maximize shareholder value.

In a phase II trial of Picoplatin in small cell lung cancer, the median overall survival was 27 weeks in patients who received Picoplatin and median progression-free survival was 9 weeks. The six-month and one-year survival rates in patients administered Picoplatin were 51% and 17%, respectively.

The current medical treatments for refractory and resistant small cell lung cancer patients often include palliative best supportive care and there is no approved therapy in the U.S. for this patient population. Best supportive care has been shown previously to have a median overall survival of 14 weeks.

Picoplatin is a new generation platinum chemotherapy agent that is being studied in a variety of cancers, treatment combinations and by two routes of administration -- intravenous and capsule formulation. Picoplatin was licensed to Poniard in April 2004 by Canada-based *AnorMed. (*AnorMed was acquired by Genzyme Inc. in 2006).

The clinical trials of intravenous Picoplatin include the SPEAR trial in small cell lung cancer and two phase II trials in metastatic colorectal and hormone-refractory prostate cancers. A phase 1 clinical trial of oral Picoplatin in patients with solid tumors is also currently underway.

Poniard will also be submitting updated data from the phase II trial in colorectal cancer and the final phase I cardiac safety trial results at the AACR - NCI - EORTC Symposium to be held in Boston, November 15-19.

The upcoming phase III study of Picoplatin is a major binary event for Poniard Pharma and though investing in this stock is risky, it could be lucrative, should the trial prove successful.

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2009 RTTNews.com, Inc. All Rights Reserved

Share This

|   More

Trading Corner

Free Newsletters!

Choose one or all of the following newsletters:

6 Free Issues of Trading 101 Newsletter

Trading 101 Newsletter

Options 101
By Bernie Schaeffer

Want to learn more about Options trading? Read this article and get a "primer" from avid investor Bernie Schaeffer, founder of Schaeffer's Investment Research, on options. Learn what puts and calls are (with charts) along with why investors/traders should consider options in their portfolios. Plus more!


6 Free Issues of Trading 201 Newsletter

Trading 201 Newsletter

So, You Want to Trade Forex: Understanding Forex in Plain English

By Raghee Horner, Founder / Lead Trader of EZ2TradeSoftware.com

Get the inside scoop on a hot trading topic! Check out this article on the basics of Forex trading by Forex trader and owner of EZ2TradeSoftware.com, Raghee Horner. And, see what else Trading 201 has to offer. It's six months of FREE investment information from masters of the trade.


Fast Break - A Weekly Newsletter for Futures Traders

Fast Break Newsletter

Fast Break's timely content brings you a high-level look at and in-depth view of current market moves, trends and events, plus analysis, tips and market reviews, as well as trading techniques, pointers and tools you can use immediately.

Sign up, compliments of eSignal, and discover the futures trading advantage you shouldn't be without.


Market data delayed per exchange rules. All quotes are in U.S. Eastern Time (EST).
© 2009 eSignal, Inc., a wholly owned subsidiary of Interactive Data Corporation (NYSE: IDC). All rights reserved.
Terms and Conditions    Privacy Policy    Trademarks    More